Varex Imaging Corporation (VREX) P/E Ratio History
Deep ValueTrading at -5.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2017–2024
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Varex Imaging Corporation (VREX) trades at a price-to-earnings ratio of -5.9x, with a stock price of $9.98 and trailing twelve-month earnings per share of $-1.97.
The current P/E is 110% below its 5-year average of 58.1x. Over the past five years, VREX's P/E has ranged from a low of 19.0x to a high of 229.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, VREX trades at a 126% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, VREX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VREX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VREX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VREX P/E vs Peers
Imaging, radiation, and oncology devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $17B | 30.5 | - | -25% | |
| $144B | 51.6 | 2.37Best | +23% | |
| $4B | 96.5 | 64.63 | +104% | |
| $390B | 45.8 | 3.88 | +36% | |
| $30B | 14.3Lowest | - | +5% | |
| $127B | 39.3 | 2.65 | +8% | |
| $26B | 25.7 | - | +224%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VREX Historical P/E Data (2017–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q3 | Jun 28 2024 | $14.73 | $0.69 | 21.5x | -58% |
| FY2024 Q2 | Mar 29 2024 | $18.10 | $0.83 | 21.8x | -58% |
| FY2024 Q1 | Dec 29 2023 | $20.50 | $0.90 | 22.8x | -56% |
| FY2023 Q4 | Sep 30 2023 | $18.79 | $0.99 | 19.0x | -63% |
| FY2023 Q3 | Jun 30 2023 | $23.57 | $0.68 | 34.8x | -32% |
| FY2023 Q2 | Mar 31 2023 | $18.19 | $0.70 | 26.1x | -49% |
| FY2023 Q1 | Dec 30 2022 | $20.30 | $0.78 | 26.1x | -49% |
| FY2022 Q4 | Sep 30 2022 | $21.14 | $0.73 | 29.0x | -44% |
| FY2022 Q3 | Jul 01 2022 | $21.33 | $0.61 | 35.0x | -32% |
| FY2022 Q2 | Apr 01 2022 | $21.33 | $0.70 | 30.5x | -41% |
| FY2022 Q1 | Dec 31 2021 | $31.55 | $0.60 | 52.6x | +2% |
| FY2021 Q4 | - | $28.20 | $0.41 | 68.8x | +34% |
| FY2020 Q2 | Apr 03 2020 | $20.73 | $0.09 | 229.3x | +347% |
| FY2020 Q1 | Jan 03 2020 | $30.00 | $0.29 | 103.6x | +102% |
| FY2019 Q4 | Sep 30 2019 | $28.54 | $0.40 | 70.7x | +38% |
| FY2019 Q3 | Jun 28 2019 | $30.65 | $0.20 | 150.7x | +194% |
| FY2019 Q2 | Mar 29 2019 | $33.88 | $0.34 | 99.6x | +94% |
| FY2019 Q1 | Dec 28 2018 | $23.63 | $0.51 | 46.3x | -10% |
| FY2018 Q4 | Sep 30 2018 | $28.66 | $0.73 | 39.3x | -24% |
| FY2018 Q3 | Jun 29 2018 | $37.09 | $1.11 | 33.4x | -35% |
| FY2018 Q2 | Mar 30 2018 | $35.78 | $1.29 | 27.7x | -46% |
| FY2018 Q1 | Dec 29 2017 | $40.17 | $1.37 | 29.3x | -43% |
| FY2017 Q4 | Sep 30 2017 | $33.84 | $1.37 | 24.7x | -52% |
| FY2017 Q3 | Jun 30 2017 | $33.80 | $1.57 | 21.5x | -58% |
| FY2017 Q2 | Mar 31 2017 | $33.60 | $1.75 | 19.2x | -63% |
Average P/E for displayed period: 51.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VREX — Frequently Asked Questions
Quick answers to the most common questions about buying VREX stock.
What is VREX's P/E ratio?
Varex Imaging Corporation (VREX) trailing twelve-month P/E ratio is -5.9x, based on TTM diluted EPS of $-1.97. The 5-year average P/E is 58.1x and the historical range spans 19.0x to 229.3x.
Is VREX stock overvalued or undervalued?
VREX trades at -5.9x P/E, below its 5-year average of 58.1x. At the 0th percentile of its historical range (19.0x–229.3x), the stock is priced at a discount to its own history.
Is VREX stock expensive?
No, VREX is not expensive on a historical basis. The current P/E of -5.9x is below the 5-year average of 58.1x and sits at the 0th percentile of its valuation range.
What is VREX's historical P/E range?
Over the past 5 years, VREX's P/E ratio has ranged from 19.0x to 229.3x, with a median of 35.0x and an average of 58.1x. The current P/E of -5.9x places the stock at the 0th percentile of this range. Full historical data spans 2017–2024.
How does VREX's P/E compare to the S&P 500?
VREX trades at -5.9x P/E versus the S&P 500 median of 25.1x. The 124% discount to the market suggests lower growth expectations or perceived higher risk.
How does VREX's valuation compare to Healthcare peers?
Varex Imaging Corporation P/E of -5.9x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VREX's PEG ratio?
VREX PEG ratio is N/A, based on a P/E of -5.9x and EPS growth of -45.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VREX's earnings yield?
VREX earnings yield is N/A, the inverse of its -5.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.